Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Daily Feeds
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Aclaris Therapeutics (ACRS)
NASDAQ:ACRS
Holding ACRS?
Track your performance easily
Earnings Data
Report Date
Feb 20, 2025TBA Not Confirmed
Period Ending
2024 (Q4)Consensus EPS Forecast
-$0.29Last Year’s EPS
-$0.02Same Quarter Last Year
Strong Buy
Based on 6 Analysts Ratings
---
Earnings Call Summary
Earnings Call Date:Nov 06, 2024
|% Change Since: 22.52%
|Next Earnings Date:Feb 20, 2025
Earnings Call Sentiment|Neutral
The earnings call highlights Aclaris' strong financial position and promising advancement of ATI-2138, despite some challenges in cash reserves and competitive landscape considerations. The company is making strategic moves in its drug development with a focus on efficiency and differentiation.Company Guidance
During the Aclaris Therapeutics Q1 2024 earnings call, several key metrics and strategic updates were provided. The company ended the first quarter with cash, cash equivalents, and marketable securities totaling $161 million, down from $182 million at the end of the previous year. Approximately $14 million of the expenditures in the first quarter were related to nonrecurring payments. Aclaris has decided to advance ATI-2138, their oral small molecule ITK JAK3 inhibitor, into a Phase II proof-of-concept study targeting atopic dermatitis. The study is designed as an open-label trial involving 15 patients over 12 weeks, with a focus on safety, pharmacokinetics (PK), and early efficacy signals. Joseph Monahan highlighted that ATI-2138 is 44.4 times more potent than ritlecitinib in blocking ITK-dependent cytokine production and 5.4 times more potent in JAK3-dependent readouts. Financially, Aclaris is committed to maintaining a strong balance sheet with ongoing cost containment initiatives and exploring business development opportunities to source nondilutive capital.Strong Financial Position
Aclaris ended the first quarter with $161 million in cash, cash equivalents, and marketable securities, with no outstanding debt. This positions the company well financially for upcoming initiatives.
Advancement of ATI-2138
Decision to move ATI-2138 forward in a proof-of-concept study for moderate to severe atopic dermatitis, showing promising preclinical and Phase I results.
Cost Containment Success
Cost containment initiatives are on track, with significant reductions in cash expenditures expected for the remainder of the year.
Potential Best-in-Class Treatment
ATI-2138 shows potential as a best-in-class dual inhibitor of ITK and JAK3, designed to treat autoimmune diseases with a favorable safety profile.
---
ACRS Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
---
ACRS Earnings-Related Price Changes
Report Date | Price 1 Day Before | Price 1 Day After | Percentage Change |
|---|---|---|---|
| Nov 06, 2024 | $2.22 | $2.26 | +1.80% |
| Aug 07, 2024 | $1.22 | $1.19 | -2.46% |
| May 07, 2024 | $1.34 | $1.22 | -8.96% |
| Feb 27, 2024 | $1.21 | $1.20 | -0.83% |
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
---
FAQ
When does Aclaris Therapeutics (ACRS) report earnings?
Aclaris Therapeutics (ACRS) is schdueled to report earning on Feb 20, 2025, TBA Not Confirmed.
What is Aclaris Therapeutics (ACRS) earnings time?
Aclaris Therapeutics (ACRS) earnings time is at Feb 20, 2025, TBA Not Confirmed.
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.
What companies are reporting earnings today?
You can see a list of the companies which are reporting today on TipRanks earnings calendar.
What is ACRS EPS forecast?
ACRS EPS forecast for the fiscal quarter 2024 (Q4) is -$0.29.
---